Quest Diagnostics Inc Proceeds from Sale of Equity Method Investments
Quest Diagnostics Inc (DGX) reported Proceeds from Sale of Equity Method Investments of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2024-02-22
- Quest Diagnostics Inc proceeds from sale of equity method investments for the quarter ending 2022-12-31 was $0.00.
- Quest Diagnostics Inc proceeds from sale of equity method investments for the quarter ending 2022-09-30 was $0.00.
- Quest Diagnostics Inc proceeds from sale of equity method investments for the quarter ending 2021-12-31 was $0.00.
- Quest Diagnostics Inc proceeds from sale of equity method investments for the quarter ending 2021-09-30 was $0.00.
- Quest Diagnostics Inc proceeds from sale of equity method investments for fiscal 2023 was $0.00.
- Quest Diagnostics Inc proceeds from sale of equity method investments for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Quest Diagnostics Inc proceeds from sale of equity method investments for fiscal 2021 was $755.00M.
- Quest Diagnostics Inc proceeds from sale of equity method investments for fiscal 2020 was $0.00.
| Period end | Proceeds from Sale of Equity Method Investments 3 month | Proceeds from Sale of Equity Method Investments 6 month | Proceeds from Sale of Equity Method Investments 9 month | Proceeds from Sale of Equity Method Investments 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-21 | $0.00 10-Q · filed 2022-10-21 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-07-22 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $755.00M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-21 | $755.00M 10-Q · filed 2022-10-21 | ||
| 2021-06-30 | $755.00M 10-Q · filed 2022-07-22 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $0.00 derived: sum of 2 quarters · filed 2023-02-21 | $0.00 10-K · filed 2023-02-21 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-22 | $0.00 10-Q · filed 2021-10-22 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-07-23 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |